tetano
Editor, Senior Moderator
MADISON, WI, July 27, 2016 ? FluGen Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of more effective influenza vaccines, today announced the initiation of the first Phase 1 clinical trial of its RedeeFlu? universal influenza vaccine. The trial is a randomized, blinded, dose-ranging Phase 1 study of the H3N2 RedeeFlu? influenza vaccine in 96 healthy adult subjects between 18 and 49 years of age. In addition to the trial?s primary goal of evaluating the safety of the vaccine in this population, the study also will evaluate both antibody and T-cell responses induced by the vaccine.
?The initiation of this first in man study is an important milestone achieved through the research and development efforts of the FluGen team and our collaborators. We believe that RedeeFlu? could be the first influenza vaccine to show robust protection from drifted or mismatched flu strains,? said Paul V. Radspinner, President & CEO.
http://flugen.com/flugen-initiates-...versal-influenza-vaccine-in-healthy-subjects/
?The initiation of this first in man study is an important milestone achieved through the research and development efforts of the FluGen team and our collaborators. We believe that RedeeFlu? could be the first influenza vaccine to show robust protection from drifted or mismatched flu strains,? said Paul V. Radspinner, President & CEO.
http://flugen.com/flugen-initiates-...versal-influenza-vaccine-in-healthy-subjects/